[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100608193":3},{"organization":4,"outcomesModule":7,"designInfo":20,"detailedDescription":11,"studyPopulation":23,"armGroups":24,"interventions":29,"overallOfficials":11,"centralContacts":34,"locations":11,"responsibleParty":40,"collaborators":11,"id":44,"slug":11,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":11,"eligibilityCriteria":48,"healthyVolunteers":45,"sex":49,"minAge":50,"maxAge":11,"enrollmentInfo":51,"targetDuration":11,"studyType":54,"phases":11,"briefSummary":55,"conditions":56,"keywords":11,"overallStatus":58,"whyStopped":11,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":11},{"fullName":5,"class":6},"Beijing GoBroad Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Progression-free survival (PFS) rate at 24 months post-administration",null,"From date ofrandomization untilhe date of first documented progression , assessed up to 24 months",[14,17],{"measure":15,"description":11,"timeFrame":16},"Progression-Free Survival (PFS)","The time from the start of cell infusion to the first assessment of progression or death from any cause， assessed up to 5 years",{"measure":18,"description":11,"timeFrame":19},"Overall Survival (OS)","From date of randomization untilhe date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years",{"allocation":11,"interventionModel":11,"interventionModelDescription":11,"primaryPurpose":11,"observationalModel":21,"timePerspective":22,"maskingInfo":11},"COHORT","PROSPECTIVE","Patients who achieve remission (complete or partial) at the 3-month post-CAR-T infusion assessment",[25],{"label":26,"type":11,"description":11,"interventionNames":27},"Maintenance Therapy Group",[28],"Drug: Maintenance Therapy Group",[30],{"type":31,"name":26,"description":32,"armGroupLabels":33,"otherNames":11},"DRUG","Patients achieving remission (complete or partial) at the 3-month post-CAR-T infusion assessment receive oral zanubrutinib capsules for maintenance therapy for 2 years.",[26],[35],{"name":36,"role":37,"phone":38,"phoneExt":11,"email":39},"kai Hu","CONTACT","15810245863","hk13610956245@163.com",{"type":41,"investigatorFullName":42,"investigatorTitle":43,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Kai Hu","Director of the Lymphoma Department at Beijing Gao Bo Hospital","100608193",false,"NCT07198373","Exploratory Study on the Efficacy of Zebutinib as Maintenance Therapy Following CAR-T Cell Therapy in Patients With Non-Hodgkin B-Cell Lymphoma","Inclusion Criteria:\n\n* (1) Age ≥ 18 years, no gender restrictions; (2) Expected survival time exceeding 12 weeks; (3) Cytologically or histopathologically confirmed diagnosis of non-Hodgkin B-cell lymphoma according to WHO 2016 criteria; (4) Platelet count ≥ 50 × 10⁹\u002FL; (5) Currently undergoing or scheduled to initiate oral zanubrutinib maintenance therapy following autologous or allogeneic CAR-T cell therapy; (6) Able to understand this trial and has signed an informed consent form.\n\nExclusion Criteria:\n\n* (1) Pregnant or lactating individuals; male subjects planning to conceive within one year of treatment or within one year after cell reinfusion, or whose partners plan to conceive within one year after cell reinfusion; (2) Individuals with medical conditions that affect their ability to sign a written informed consent form or comply with study procedures; or those unwilling or unable to adhere to study requirements; (3) Individuals deemed unsuitable for participation in this trial by the investigator.\n\n  1. Pregnant or lactating individuals; or male subjects planning to conceive within one year of treatment or within one year after cell infusion, or whose partners plan to conceive within one year after cell infusion; (2) Individuals with medical conditions that prevent signing a written informed consent form or complying with study procedures; or those unwilling or unable to comply with study requirements; (3) Individuals deemed unsuitable for this trial by the investigator.","ALL","18 Years",{"count":52,"type":53},40,"ESTIMATED","OBSERVATIONAL","This study is a single-center, Phase IV clinical trial designed to collect and analyze data on the efficacy and safety of zanubrutinib as maintenance therapy following CAR-T cell therapy in subjects with non-Hodgkin B-cell lymphoma.",[57],"B Cell Lymphoma","NOT_YET_RECRUITING","2025-09-21",{"date":61,"type":62},"2025-09-30","ACTUAL",{"date":64,"type":53},"2025-09-20",{"date":66,"type":53},"2028-12-30",{"name":5,"class":6}]